Sexually Transmitted Infections
Sexually Transmitted Infections
Sexually Transmitted Infections
infections (STIs)
22 August 2022
العربية
中文
Français
Русский
Español
Key facts
More than 1 million sexually transmitted infections (STIs) are acquired
every day worldwide, the majority of which are asymptomatic.
Each year there are an estimated 374 million new infections with 1 of 4
curable STIs: chlamydia, gonorrhea, syphilis, and trichomoniasis.
More than 500 million people 15–49 years are estimated to have a genital
infection with herpes simplex virus (HSV or herpes) (1).
Human papillomavirus (HPV) infection is associated with over 311 000
cervical cancer deaths each year (2).
Almost 1 million pregnant women were estimated to be infected with
syphilis in 2016, resulting in over 350 000 adverse birth outcomes (3).
STIs have a direct impact on sexual and reproductive health through
stigmatization, infertility, cancers, and pregnancy complications and can
increase the risk of HIV.
Drug resistance is a major threat to reducing the burden of STIs
worldwide.
Overview
More than 30 different bacteria, viruses, and parasites are known to be transmitted
through sexual contact, including vaginal, anal, and oral sex. Some STIs can also be
transmitted from mother to child during pregnancy, childbirth, and breastfeeding.
Eight pathogens are linked to the greatest incidence of STIs. Of these, 4 are
currently curable: syphilis, gonorrhea, chlamydia, and trichomoniasis. The other 4
are incurable viral infections: hepatitis B, herpes simplex virus (HSV), HIV, and
human papillomavirus (HPV).
In addition, emerging outbreaks of new infections that can be acquired by sexual
contact such as monkeypox, Shigella sonnei, Neisseria meningitides, Ebola, and
Zika, as well as re-emergence of neglected STIs such as lymphogranuloma
venereum. These herald increasing challenges in the provision of adequate services
for STIs prevention and control.
More than 1 million STIs are acquired every day. In 2020, WHO estimated 374
million new infections with 1 of 4 STIs: chlamydia (129 million), gonorrhea
(82 million), syphilis (7.1 million), and trichomoniasis (156 million). More than
490 million people were estimated to be living with genital herpes in 2016, and an
estimated 300 million women have an HPV infection, the primary cause of cervical
cancer and anal cancer among men who have sex with men. An estimated
296 million people are living with chronic hepatitis B globally.
STIs can have serious consequences beyond the immediate impact of the infection
itself.
STIs like herpes, gonorrhea, and syphilis can increase the risk of HIV
acquisition.
Mother-to-child transmission of STIs can result in stillbirth, neonatal death, low-
birth weight and prematurity, sepsis, neonatal conjunctivitis, and congenital
deformities.
HPV infection causes cervical and other cancers.
Hepatitis B resulted in an estimated 820 000 deaths in 2019, mostly from
cirrhosis and hepatocellular carcinoma. STIs such as gonorrhea and chlamydia
are major causes of pelvic inflammatory disease and infertility in women.
Prevention of STIs
When used correctly and consistently, condoms offer one of the most effective
methods of protection against STIs, including HIV. Although highly effective,
condoms do not offer protection for STIs that cause extra-genital ulcers (i.e., syphilis
or genital herpes). When possible, condoms should be used in all vaginal and anal
sex.
Safe and highly effective vaccines are available for 2 viral STIs: hepatitis B and HPV.
These vaccines have represented major advances in STI prevention. By the end of
2020, the HPV vaccine had been introduced as part of routine immunization
programs in 111 countries, primarily high- and middle-income countries. To eliminate
cervical cancer as a public health problem globally, high coverage targets for HPV
vaccination, screening and treatment of precancerous lesions, and management of
cancer must be reached by 2030 and maintained at this high level for decades.
Research to develop vaccines against genital herpes and HIV is advanced, with
several vaccine candidates in early clinical development. There is mounting
evidence suggesting that the vaccine prevents meningitis (MenB) and provides some
cross-protection against gonorrhea. More research into vaccines for chlamydia,
gonorrhea, syphilis, and trichomoniasis are needed.
Other biomedical interventions to prevent some STIs include adult voluntary medical
male circumcision, microbicides, and partner treatment. There are ongoing trials to
evaluate the benefit of pre-and post-exposure prophylaxis of STIs and their potential
safety weighed with antimicrobial resistance (AMR).
Diagnosis of STIs
STIs are often asymptomatic. When symptoms occur, they can be non-specific.
Moreover, laboratory tests rely on blood, urine, or anatomical samples. Three
anatomical sites can carry at least one STI. These differences are modulated by sex
and sexual risk. These differences can mean the diagnosis of STIs is often missed
and individuals are frequently treated for 2 or more STIs.
Accurate diagnostic tests for STIs (using molecular technology) are widely used in
high-income countries. These are especially useful for the diagnosis of
asymptomatic infections. However, they are largely unavailable in low- and middle-
income countries (LMICs) for chlamydia and gonorrhea. Even in countries where
testing is available, it is often expensive and not widely accessible. In addition, the
time it takes for results to be received is often long. As a result, follow-up can be
impeded and care or treatment can be incomplete.
On the other hand, inexpensive, rapid tests are available for syphilis, hepatitis B, and
HIV. The rapid syphilis test and rapid dual HIV/syphilis tests are used in several
resource-limited settings.
Several other rapid tests are under development and have the potential to improve
STI diagnosis and treatment, especially in resource-limited settings.
Treatment of STIs
Effective treatment is currently available for several STIs.
Three bacterial (chlamydia, gonorrhea, and syphilis) and one parasitic STI
(trichomoniasis) are generally curable with existing single-dose regimens of
antibiotics.
For herpes and HIV, the most effective medications available are antivirals that
can modulate the course of the disease, though they cannot cure the disease.
For hepatitis B, antivirals can help fight the virus and slow damage to the liver.
AMR of STIs – in particular gonorrhea – has increased rapidly in recent years and
has reduced treatment options. The Gonococcal AMR Surveillance Programme
(GASP) has shown high rates of resistance to many antibiotics including quinolone,
azithromycin, and extended-spectrum cephalosporins, a last-line treatment (4).
AMR for other STIs like Mycoplasma genitalium, though less common, also exists.
Information, education, and counseling can improve people’s ability to recognize the
symptoms of STIs and increase the likelihood that they will seek care and encourage
a sexual partner to do so. Unfortunately, lack of public awareness, lack of training
among health workers, and long-standing, widespread stigma around STIs remain
barriers to greater and more effective use of these interventions.
People seeking screening and treatment for STIs face numerous problems. These
include limited resources, stigmatization, poor quality of services, and often out-of-
pocket expenses.
Some populations with the highest rates of STIs – such as sex workers, men who
have sex with men, people who inject drugs, prison inmates, mobile populations, and
adolescents in high-burden countries for HIV – often do not have access to adequate
and friendly health services.
In many settings, STI services are often neglected and underfunded. These
problems lead to difficulties in providing testing for asymptomatic infections,
insufficient number of trained personnel, limited laboratory capacity, and inadequate
supplies of appropriate medicines.
WHO response
Our work is currently guided by the Global health sector strategy on HIV, Hepatitis,
and Sexually Transmitted Infections, 2022–2030. Within this framework, WHO:
develops global targets, norms, and standards for STI prevention, testing, and
treatment;
supports the estimation and economic burden of STIs and the strengthening of
STI surveillance;
globally monitors AMR to gonorrhea; and
leads the setting of the global research agenda on STIs, including the
development of diagnostic tests, vaccines, and additional drugs for gonorrhea
and syphilis.
References
1. James C, Harfouche M, Welton NJ, et al. Herpes simplex virus: global infection
prevalence and incidence estimates, 2016. Bull World Health Organ.
2020;98(5):315-329.
2. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer
statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for
36 cancers in 185 countries. CA Cancer J Clin. 2018 Nov;68(6):394-424. Epub
2018 Sep 12. Erratum in: CA Cancer J Clin. 2020 Jul;70(4):313.
3. Unemo M, Lahra MM, Escher M, Eremin S, Cole MJ, Galarza P, Ndowa F,
Martin I, Dillon JR, Galas M, Ramon-Pardo P, Weinstock H, Wi T. WHO global
antimicrobial resistance surveillance (GASP/GLASS) for Neisseria gonorrhoeae
2017-2018: a retrospective observational study. Lancet Microbe 2021; 2: e627–
36
Share
Twitter
Email
Print
By reading this page you agree to ACOG's Terms and Conditions. Read
terms
Number 678 (Reaffirmed 2020)
Committee on Adolescent Health Care
This Committee Opinion was developed by the American College of
Obstetricians and Gynecologists Committee on Adolescent Health Care in
collaboration with committee member Joanna H. Stacey, MD.
This document reflects emerging clinical and scientific advances as of the
date issued and is subject to change. The information should not be
construed as dictating an exclusive course of treatment or procedure to
be followed.
Effective Programs
Data have shown that not all programs are equally effective for all ages,
races and ethnicities, socioeconomic groups, and geographic areas; there
is no “one size fits all” program. However, one key component of an
effective program is to encourage community-centered efforts. Innovative,
multicomponent, community-wide initiatives that use evidence-based
adolescent pregnancy prevention interventions and reproductive health
services (including inclusion of moderately or highly effective
contraceptive methods, such as long-acting reversible contraception)
have dramatically reduced pregnancy rates among African American and
Hispanic individuals aged 15–19 years old 10. Although formal sex
education varies in content across schools, studies have demonstrated
that comprehensive sex education programs reduce the rates of sexual
activity, sexual risk behaviors (eg, number of partners and unprotected
intercourse), STIs, and adolescent pregnancy 11. However, despite
concerns raised by some involved in health education, a study of four
select abstinence-only education programs reported no increase in the
risk of adolescent pregnancy, STIs, or the rates of adolescent sexual
activity compared with students in a control group 12.
References
1. Concerns regarding social media and health issues in adolescents and
young adults. Committee Opinion No. 653. American College of
Obstetricians and Gynecologists. Obstet Gynecol 2016;127:e62–5.
[PubMed] [Obstetrics & Gynecology]
Article Locations:
Article Location
Article Location
Article Location
Article Location
Article Location
Article Location
Article Location
Article Location
11. Chin HB, Sipe TA, Elder R, Mercer SL, Chattopadhyay SK, Jacob V, et al.
The effectiveness of group-based comprehensive risk-reduction and
abstinence education interventions to prevent or reduce the risk of
adolescent pregnancy, human immunodeficiency virus, and sexually
transmitted infections: two systematic reviews for the Guide to
Community Preventive Services. Community Preventive Services Task
Force. Am J Prev Med 2012;42:272–94. [PubMed] [Full Text]
Article Locations:
Article Location
Article Location
13. Quint EH. Adolescents with special needs: clinical challenges in
reproductive health care. J Pediatr Adolesc Gynecol 2016;29:2–6. [PubMed]
[Full Text]
Article Locations:
Article Location
Article Location
15. Common Sense Media. Social media, social life: how teens view their
digital lives. San Francisco (CA): Common Sense Media; 2012. Available
at: https://www.commonsensemedia.org/research/social-media-social-life-
how-teens-view-their-digital-lives. Retrieved June 27, 2016.
Article Locations:
Article Location
Article Location
17. Carter MW, Tregear ML, Moskosky SB. Community education for family
planning in the U.S.: a systematic review. Am J Prev Med 2015;49:S107–
15. [PubMed] [Full Text]
Article Locations:
Article Location
18. Bull SS, Levine DK, Black SR, Schmiege SJ, Santelli J. Social media-
delivered sexual health intervention: a cluster randomized controlled trial.
Am J Prev Med 2012;43:467–74. [PubMed] [Full Text]
Article Locations:
Article Location
https://www.acog.org/clinical/clinical-guidance/committee-opinion/articles/2016/11/
comprehensive-sexuality-education